Total votes: 4

Cash: $3.97M as of 30th June 2009

Cytopia is an Australian biotechnology company focused on the discovery and development of new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco with 2 lead compounds of note

CYT997, a vascular disrupting agent for the treatment of various cancers: The lead program for the Company is CYT997, a vascular disrupting agent for the treatment of various cancers, in Phase II clinical studies. CYT997 is a novel compound synthesized by Cytopia’s chemistry team which possesses potent vascular disrupting properties against tumour blood vessels. By attacking tumour vessels, the compound may lead to blood flow arrest, starvation of rapidly dividing tumour cells and tumour death. As well as its potent anti-vascular properties, the compound may also directly effect tumour cell replication via its inhibition of the cellular structural protein, tubulin.

Unlike many other antivascular agents, including those more advanced in clinical development (e.g. Zybrestat from Oxigene and ASA404 from Antisoma), CYT997 can possibly be administered both intravenously and orally, allowing patients to be dosed more frequently and more conveniently by mouth.

CYT387 for myeloma: The company is also enrolling in a Phase II programme in relapsed or refractory multiple myeloma. Myeloproliferative disorders (MPDs) are debilitating, and potentially fatal, diseases of blood cell production. Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease, cancer and pulmonary hypertension (PAH). The company's lead drug, CYT387, will enter a Phase I/II clinical trials in late 2009.

Companies possibly related to same therapeutic field:
 - Chemgenex
       - http://www.bioinvest.com.au/company/Chemgenex
 - EpiCept for AML - see USA sister website, USA site requires separate log-in
 - Vion Phase III for AML  - see USA sister website, USA site requires separate log-in